NAUT (Nautilus Biotechnology) EBIT: $-64.12 Mil (TTM As of Mar. 2026)

What is Nautilus Biotechnology EBIT?

Nautilus Biotechnology NAUT +1.51% 28 EBIT is $-64.12 Mil as of Mar. 2026. GuruFocus rates NAUT with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Nautilus Biotechnology's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-16.12 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-64.12 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nautilus Biotechnology's annualized ROC % for the quarter that ended in Mar. 2026 was -72.83%. Nautilus Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -209.76%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nautilus Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -27.53%.

Nautilus Biotechnology (NAS:NAUT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nautilus Biotechnology's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-64.496 * ( 1 - 0% )	/	( (91.678	+	85.442)	/ 2 )
=	-64.496	/	88.56
=	-72.83 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	191.112	-	1.423	-	( 103.406	-	max(0, 7.952	-	105.963	+	103.406	))
=	91.678

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	177.779	-	1.848	-	( 95.869	-	max(0, 8.343	-	98.832	+	95.869	))
=	85.442

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Nautilus Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-64.496	/	( ( (31.23 + max(-1.563, 0))	+	(30.266 + max(-1.528, 0)) )	/	2 )
=	-64.496	/	( ( 31.23	+	30.266 )	/	2 )
=	-64.496	/	30.748
=	-209.76 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.557)	-	(1.423	+	0	+	2.697)
=	-1.563

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.963)	-	(1.848	+	0	+	2.643)
=	-1.528

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nautilus Biotechnology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-64.117	/	232.911
	=	-27.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nautilus Biotechnology EBIT Related Terms

Nautilus Biotechnology EBIT Historical Data

* Premium members only.

The historical data trend for Nautilus Biotechnology's EBIT can be seen below:

Nautilus Biotechnology EBIT Chart

Nautilus Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-50.50

-63.62

-76.15

-81.48

-66.84

Nautilus Biotechnology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-18.84	-17.10	-15.47	-15.42	-16.12

NAUT vs IFRX, NMRA, IRD: EBIT Comparison

For the Biotechnology subindustry, Nautilus Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nautilus Biotechnology EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's EV-to-EBIT falls into.

Save Embed

28GF Score

Nautilus Biotechnology Inc NAUT

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nautilus Biotechnology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.12 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-64.12 Mil mean?

Nautilus Biotechnology (NAUT) has a EBIT of $-64.12 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nautilus Biotechnology.

Is Nautilus Biotechnology's EBIT too high?

Nautilus Biotechnology's current EBIT is $-64.12 Mil. Overall, Nautilus Biotechnology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Nautilus Biotechnology's EBIT compare to IFRX and NMRA?

Nautilus Biotechnology's EBIT of $-64.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nautilus Biotechnology. Nautilus Biotechnology's current EBIT is $-64.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nautilus Biotechnology stock overvalued right now?

Nautilus Biotechnology (NAUT) has a current EBIT of $-64.12 Mil. The current EBIT is $-64.12 Mil. Nautilus Biotechnology's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Nautilus Biotechnology (NAUT), the current EBIT is $-64.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nautilus Biotechnology Business Description

Industry Healthcare Biotechnology

Comparable Companies IFRX NMRA IRD IVVD RCKT RGNX LRMR GLSI LCTX PBYI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 2701 Eastlake Avenue East, Seattle, WA, USA, 98102

Website https://www.nautilus.bio

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

28GF Score

Get the complete analysis for NAUT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36

Price

View NAUT Analysis

See EBIT data for all stocks →